Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

103.46
BATS BZX Real-Time Price
As of 1:05pm ET
 -0.28 / -0.27%
Today’s Change
43.86
Today|||52-Week Range
121.70
+41.51%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$18.6B

Company Description

Incyte Corp. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs. The company's product, Jakafi (ruxolitinib), a JAK1 and JAK2 inhibitor, is currently approved in the U.S. for the treatment of intermediate or high-risk myelofibrosis and is in development as a potential treatment for other cancers. Incyte was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Contact Information

Incyte Corp.
1801 Augustine Cut-Off
Wilmington Delaware 19803
P:(302) 498-6700
Investor Relations:
(302) 498-5914

Employees

Shareholders

Mutual fund holders63.43%
Other institutional32.42%
Individual stakeholders11.88%

Top Executives

Hervé HoppenotPresident, Chief Executive Officer & Director
David W. GryskaChief Financial Officer & Executive Vice President
Reid M. HuberChief Scientific Officer & Executive VP
Steven H. SteinChief Medical Officer & Senior Vice President
Richard S. LevyChief Drug Development Officer & Executive VP